The role of prostaglandin E2 in endometriosis

Gynecological Endocrinology

Volumn 28, Issue 2, 2012, Pages 134-138

  Sacco, Keith ^a   Portelli, Mark ^a   Pollacco, Jol ^a   Schembri Wismayer, Pierre ^a   Calleja Agius, Jean ^a,b  

^a UNIVERSITY OF MALTA   (Malta)

^b MATER DEI HOSPITAL   (Malta)

Author keywords

Endometriosis; Estrogens; Infertility; Prostaglandins

Indexed keywords

ANDROGEN; AROMATASE; AROMATASE INHIBITOR; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DANAZOL; DIENOGEST; ESTROGEN; FIBROBLAST GROWTH FACTOR 9; GELATINASE A; GONADORELIN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 1BETA; ORAL CONTRACEPTIVE AGENT; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN H2; PROTEIN KINASE C DELTA; STEROIDOGENIC ACUTE REGULATORY PROTEIN; STEROIDOGENIC FACTOR 1; TRANSCRIPTION FACTOR ELK 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; ENDOMETRIOSIS; ESTROGEN SYNTHESIS; HOT FLUSH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LAPAROSCOPY; LIBIDO; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIDE EFFECT; UPREGULATION;

APOPTOSIS; CELL PROLIFERATION; DINOPROSTONE; ENDOMETRIOSIS; ESTROGENS; FEMALE; HUMANS; IMMUNOSUPPRESSION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84856111677     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.588753     Document Type: Article

References (82)

1. Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins inpathology of the endometrium. Reproduction 2003; 126: 559-567. (Pubitemid 37540615)
2. Wu MH, Sun HS, Lin CC, Hsiao KY, Chuang PC, Pan HA, Tsai SJ. Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis. Mol Hum Reprod 2002; 8: 1103-1110. (Pubitemid 36032848)
3. Rees MC. Heavy, painful periods. Baillieres Clin Obstet Gynaecol 1989; 3: 341-356. (Pubitemid 19277335)
4. Hofmann GE, Rao CV, Barrows GH, Sanfilippo JS. Topography of human uterine prostaglandin E and F2 alpha receptors and their profiles during pathological states. J Clin Endocrinol Metab 1983; 57: 360-366. (Pubitemid 13032490)
5. Ozkan S, Murk W, Arici A. Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci 2008; 1127: 92-100. (Pubitemid 351563100)
6. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci 2002; 955: 11-22; discussion 34. (Pubitemid 34271058)
7. Garai J, Molnar V, Varga T, Koppan M, Torok A, Bodis J. Endometriosis: harmful survival of an ectopic tissue. Front Biosci 2006; 11: 595-619. (Pubitemid 43258166)
8. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006; 12: 179-189. (Pubitemid 43231450)
9. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006; 85: 1307-1318.
10. Farquhar C. Endometriosis. BMJ 2007; 334: 249-253. (Pubitemid 46225604)
11. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissues into the peritoneal cavity. Am J Obstet Gynecol 1927; 14: 422-469.
12. Coddington CC, Jensen JR. Evolving Spectrum: The pathogenesis of Endometriosis. Clinical Obstetrics and Gynaecology 2010; 53: 380.
13. Iwanoff NS. Drusiges cysthaltiges Uterusfibromyom compliziert durch Sarcom und Carcinom (Adenofibromyoma cysticum arcomatodes carcinomatosum). Monatsch.Geburtsh.Gyndkol 1898: 295-300.
14. Levander G, Normann P. The pathogenesis of endometriosis; an experimental study. Acta Obstet Gynecol Scand 1955; 34: 366-398.
15. Robboy SJ, Bean SM. Pathogenesis of endometriosis. Reprod Biomed Online 2010; 21: 4-5.
16. Dizerega GS, Barber DL, Hodgen GD. Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression. Fertil Steril 1980; 33: 649-653. (Pubitemid 10059233)
17. Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM, Agarwal VR, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997; 82: 600-606. (Pubitemid 27068636)
18. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, Johns A, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999; 6: 293-301. (Pubitemid 29260065)
19. Bulun SE, Gurates B, Fang Z, Tamura M, Sebastian S, Zhou J, Amin S, Yang S. Mechanisms of excessive estrogen formation in endometriosis. J Reprod Immunol 2002; 55: 21-33. (Pubitemid 34626149)
20. Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001; 16: 561-566. (Pubitemid 32218810)
21. Wu MH, Lu CW, Chuang PC, Tsai SJ. Prostaglandin E2: the master of endometriosis? Exp Biol Med (Maywood) 2010; 235: 668-677.
22. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-33160. (Pubitemid 27010118)
23. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-492.
24. Ashby B. Co-expression of prostaglandin receptors with opposite effects: a model for homeostatic control of autocrine and paracrine signaling. Biochem Pharmacol 1998; 55: 239-246. (Pubitemid 28021734)
25. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226. (Pubitemid 29473315)
26. Sugimoto Y, Negishi M, Hayashi Y, Namba T, Honda A, Watabe A, Hirata M, et al. Two isoforms of the EP3 receptor with different carboxylterminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. J Biol Chem 1993; 268: 2712-2718. (Pubitemid 23057900)
27. Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, Abramovitz M, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998; 95: 15792-15797.
28. Bhattacharya M, Peri K, Ribeiro-da-Silva A, Almazan G, Shichi H, Hou X, Varma DR, Chemtob S. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 1999; 274: 15719-15724.
29. Attar E, Tokunaga H, Imir G, Yilmaz MB, Redwine D, Putman M, Gurates B, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab 2009; 94: 623-631.
30. Mathieu AP, Lavigne P, LeHoux JG. Molecular modeling and structurebased thermodynamic analysis of the StAR protein. Endocr Res 2002; 28: 419-423. (Pubitemid 36042495)
31. Tsai CF, Lii CK, Yang JJ, Liu K, Lin WL, Chen HW. Prostaglandin E2 is involved in the increase of cytochrome P-450 2B1 expression by alphatocopheryl succinate in primary rat hepatocytes in the presence of phenobarbital. Nutr Cancer 2001; 41: 188-195. (Pubitemid 34666240)
32. Sun HS, Hsiao KY, Hsu CC, Wu MH, Tsai SJ. Transactivation of steroidogenic acute regulatory protein in human endometriotic stromalcells is mediated by the prostaglandin EP2 receptor. Endocrinology 2003; 144: 3934-3942. (Pubitemid 37088748)
33. Zeitoun K, Takayama K, Michael MD, Bulun SE. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol 1999; 13: 239-253. (Pubitemid 29067999)
34. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000; 76: 320-325.
35. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996; 56: 733-737. (Pubitemid 26060513)
36. Haining RE, Cameron IT, van Papendorp C, Davenport AP, Prentice A, Thomas EJ, Smith SK. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues. Hum Reprod 1991; 6: 1200-1205.
37. Cooke PS, Buchanan DL, Lubahn DB, Cunha GR. Mechanism of estrogen action: lessons from the estrogen receptor-alpha knockout mouse. Biol Reprod 1998; 59: 470-475. (Pubitemid 28395059)
38. Wing LY, Chuang PC, Wu MH, Chen HM, Tsai SJ. Expression and mitogenic effect of fibroblast growth factor-9 in human endometriotic implant is regulated by aberrant production of estrogen. J Clin Endocrinol Metab 2003; 88: 5547-5554.
39. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A. Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. Nature 1991; 354: 531-534.
40. Tsai SJ, Wu MH, Chen HM, Chuang PC, Wing LY. Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology 2002; 143: 2715-2721.
41. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340. (Pubitemid 27157312)
42. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991; 1083: 121-134.
43. Dmowski WP, Gebel HM, Braun DP. The role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand Suppl 1994; 159: 7-14. (Pubitemid 24174510)
44. Osteen KG, Yeaman GR, Bruner-Tran KL. Matrix metalloproteinases and endometriosis. Semin Reprod Med 2003; 21: 155-164.
45. Osteen KG, Igarashi TM, Bruner-Tran KL. Progesterone action in the human endometrium: induction of a unique tissue environment which limits matrix metalloproteinase (MMP) expression. Front Biosci 2003; 8: d78-d86. (Pubitemid 39089047)
46. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 2001; 12: 489-495. (Pubitemid 32980296)
47. Chuang PC, Wu MH, Shoji Y, Tsai SJ. Downregulation of CD36 results in reduced phagocytic ability of peritoneal macrophages of women with endometriosis. J Pathol 2009; 219: 232-241.
48. Chuang PC, Lin YJ, Wu MH, Wing LY, Shoji Y, Tsai SJ. Inhibition of CD36-dependent phagocytosis by prostaglandin E2 contributes to the development of endometriosis. Am J Pathol 2010; 176: 850-860.
49. May K, Becker CM. Endometriosis and angiogenesis. Minerva Ginecol 2008; 60: 245-254.
50. Becker CM, D'Amato RJ. Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 2007; 74: 121-130. (Pubitemid 350051024)
51. Williams JA, Pontzer CH, Shacter E. Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J Interferon Cytokine Res 2000; 20: 291-298. (Pubitemid 30169740)
52. Lin YJ, Lai MD, Lei HY, Wing LY. Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 2006; 147: 1278-1286.
53. Lebovic DI, Bentzien F, Chao VA, Garrett EN, Meng YG, Taylor RN. Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1beta. Mol Hum Reprod 2000; 6: 269-275. (Pubitemid 30120622)
54. Huang C, Sheikh F, Hollander M, Cai C, Becker D, Chu PH, Evans S, Chen J. Embryonic atrial function is essential for mouse embryogenesis, cardiac morphogenesis and angiogenesis. Development 2003; 130: 6111-6119. (Pubitemid 38008812)
55. Osteen KG, Bruner-Tran KL, Ong D, Eisenberg E. Paracrine mediators of endometrial matrix metalloproteinase expression: potential targets for progestin-based treatment of endometriosis. Ann N Y Acad Sci 2002; 955: 139-146. (Pubitemid 34271071)
56. Groothuis PG, Nap AW, Winterhager E, Grummer R. Vascular development in endometriosis. Angiogenesis 2005; 8: 147-156. (Pubitemid 41712844)
57. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002; 955: 89-100; discussion 118, 396. (Pubitemid 34271066)
58. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998; 13: 1686-1690. (Pubitemid 28310515)
59. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996; 11: 220-223. (Pubitemid 26047702)
60. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007; 13: 331-342. (Pubitemid 47062827)
61. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 2008; 283: 2139-2146.
62. Itoh H, Pratt RE, Ohno M, Dzau VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992; 19: 758-761.
63. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356-363. (Pubitemid 23200200)
64. Namkoong S, Lee SJ, Kim CK, Kim YM, Chung HT, Lee H, Han JA, et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 2005; 37: 588-600. (Pubitemid 43143521)
65. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, Pozzi A. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 2007; 282: 16959-16968. (Pubitemid 47093223)
66. Huang HY. Medical treatment of endometriosis. Chang Gung Med J 2008; 31: 431-440.
67. Waller KG, Shaw RW. GnRH analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993; 59: 511-515. (Pubitemid 23086304)
68. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003; 21: 209-222.
69. Buttram VC Jr, Reiter RC, Ward S. Treatment of endometriosis with danazol: report of a 6-year prospective study. Fertil Steril 1985; 43: 353-360. (Pubitemid 15111119)
70. Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004; 81: 1395-1398. (Pubitemid 38609330)
71. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 2011; 76: 60-67.
72. Shimizu Y, Takeuchi T, Mita S, Mizuguchi K, Kiyono T, Inoue M, Kyo S. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 2009; 15: 693-701.
73. McCormack PL. Dienogest: a review of its use in the treatment of endometriosis. Drugs 2010; 70: 2073-2088.
74. Moore C. Influence of dienogest on ovulation in young fertile women. Clin Drug Invest 1999; 18: 271-278. (Pubitemid 29520772)
75. Okada H, Nakajima T, Yoshimura T, Yasuda K, Kanzaki H. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod 2001; 7: 341-347. (Pubitemid 32288323)
76. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 2005; 83: 1530-1535. (Pubitemid 40615830)
77. Foster RH, Wilde MI. Dienogest. Drugs 1998; 56: 825-33; discussion 834.
78. Winkel CA, Scialli AR. Medical and surgical therapies for pain associated with endometriosis. J Womens Health Gend Based Med 2001; 10: 137-162. (Pubitemid 32243835)
79. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2007; CD000068.
80. Couzin J. Medicine. Estrogen's ties to COX-2 may explain heart disease gender gap. Science 2004; 306: 1277. (Pubitemid 39532478)
81. Couzin J. Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 2004; 306: 1673-1675. (Pubitemid 39601361)
82. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25: 633-641.